Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Haemonetics Q4 Earnings Call Highlights
Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.
